深圳瑞捷(300977.SZ):2022年度擬使用閒置自有資金不超3.5億元購買理財產品
格隆匯12月14日丨深圳瑞捷(300977.SZ)公佈,公司於2021年12月14日召開第二屆董事會第三次會議和第二屆監事會第三次會議,審議通過了《關於2022年度使用閒置自有資金購買理財產品的議案》,同意公司及子公司2022年度擬使用閒置自有資金不超過人民幣3.5億元(含)購買商業銀行、證券公司、信託公司、基金管理公司發行的安全性較高、流動性較好、期限較短(不超過12月)的中低風險投資理財產品。該額度自股東大會審議通過之日起兩年內有效,在該額度內,資金可以滾動使用,該事項尚需公司股東大會審議,
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.